Once-Weekly Oral ART Matches Daily ART for Viral Suppression
A phase 2b trial presented at AIDS 2026 found once-weekly oral ART with islatravir/ulonivirine (ISL/ULO) maintained viral suppression at 24 weeks in 94.9% of 74 switch patients versus 97.5% of 77 continuing on daily BIC/FTC/TAF. Adverse events were similar overall, but drug-related events were higher with ISL/ULO (13% vs 0%). Trial funded by Merck.
How this was made
The 30-second read
Why it matters
For traders, the actionable signal is pipeline progress toward phase 3 and the reported efficacy/safety comparability versus daily bictegravir/emtricitabine/tenofovir alafenamide (BIC/FTC/TAF). However, the lack of phase 3 results or regulatory filings limits immediate repricing.
Market read
Conference-stage efficacy and safety comparability for once-weekly oral HIV regimens supports bullish pipeline sentiment for Merck and Gilead, but it is not yet a regulatory or commercial inflection.
What to watch
The article notes more drug-related adverse events with ISL/ULO (though grade 1-2) and an open-label switch design; phase 3 endpoints and durability are the key unknowns.
Background
The article reports phase 2b data for once-weekly oral islatravir/ulonivirine (ISL/ULO) and references phase 3 ISL/LEN trials, positioning long-acting oral ART as an adherence and stigma-reduction option.
Ticker impact
Merck funded the phase 2b ISL/ULO once-weekly ART trial and plans to submit related phase 3 data for regulatory approval.
Modest upside bias on pipeline optimism; larger repricing likely only after phase 3 efficacy/safety and regulatory milestones.
The article reports phase 2b efficacy and safety comparability, plus phase 3 SYMPHORIA initiation, but provides no regulatory decision or phase 3 results yet.
Gilead is named as the company that will submit phase 3 ISL/LEN trial data for regulatory approval.
Potentially supportive for sentiment around long-acting HIV assets; limited near-term impact without new phase 3 results.
The text cites phase 3 trial suppression ranges and regulatory submission intent, but does not indicate a new filing, approval, or updated guidance.
Market effects
Supports the broader HIV long-acting oral regimen narrative, potentially improving sector sentiment toward once-weekly adherence-focused therapies.
Primarily global biotech sentiment; no region-specific commercial impact described.
Could influence expectations for long-acting HIV treatment standards worldwide, but regulatory timing remains uncertain.
Counterpoint
Comparable viral suppression in a selected, treatment-experienced population may not translate to broader real-world adherence, resistance patterns, or long-term safety.
Key entities
- clinical_programislatravir/ulonivirine (ISL/ULO)
Once-weekly oral ART regimen evaluated in a phase 2b trial with viral suppression comparable to daily BIC/FTC/TAF.
- clinical_programislatravir/lenacapavir (ISL/LEN)
Once-weekly oral ART regimen with phase 3 trial suppression rates cited as comparable to daily regimens.
- companyMerck
Funded the phase 2b ISL/ULO trial and is part of the regulatory submission pathway for related phase 3 data.
- companyGilead Sciences
Named as submitting phase 3 ISL/LEN trial data for regulatory approval.
